Morphogenesis, Inc.
Records under this name other than patents Morphogenesis, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,555,088 | DNA vector and transformed tumor cell vaccines Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,839,680 | DNA vector and transformed tumor cell vaccines Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,391,158 | DNA vector and transformed tumor cell vaccines Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,751,400 | DNA vector and transformed tumor cell vaccines Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,636,388 | Multi-Indication Mrna Cancer Immunotherapy Formerly held In force · High confidence | In force | High confidence | |
| US 10,682,401 | Multi-Indication Mrna Cancer Immunotherapy Formerly held In force · High confidence | In force | High confidence | |
| US 6,242,579 | Antigen found on a small subset of human hematopoietic cells which binds to monoclonal antibody MG1 Term ended Term ended Mar 21, 2020 · From the USPTO record | Term ended | Term ended Mar 21, 2020 | From the USPTO record |
| US 7,094,603 | Materials and methods for treating oncological disease Term ended Term ended Dec 4, 2019 · From the USPTO record | Term ended | Term ended Dec 4, 2019 | From the USPTO record |
| US 7,348,015 | Antigen modified cancer cell vaccines for cancer therapy Term ended Term ended Jul 11, 2019 · From the USPTO record | Term ended | Term ended Jul 11, 2019 | From the USPTO record |
| US 7,795,020 | Tumor cell vaccines Term ended Ended no later than Jan 14, 2019 · From the USPTO record | Term ended | Ended no later than Jan 14, 2019 | From the USPTO record |